Program
Sulbactam
Also written as “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)”, “Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)” and “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)”.
Its studies are mostly in Respiratory Tract Infections · Communicable Diseases · Gonorrhea · Pneumonia, Bacterial · Pneumonia, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xiangbei Welman Pharmaceutical | 30 open or running | phase 4since Dec 19, 2012 | Dec 19, 2012 | none ahead |
| Pfizer | 20 open or running | phase 4since Aug 25, 2005 | Aug 25, 2005 | none ahead |
| Innoviva Specialty Therapeutics | 11 open or running | phase 1since Jan 16, 2025 | Jan 16, 2025 | May 5, 2028phase 1 · NCT06801223 |
| Yung Shin Pharm. Ind. | 10 open or running | phase 4since Dec 8, 2022 | Dec 8, 2022 | none ahead |
Also a collaborator on its studies: entasis-therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2005First study: phase 4 study in PneumoniaNew to PfizerPfizer · NCT00137007 · 151 enrolled
- Aug 16, 2010Phase 3 study in Pneumonia, BacterialPfizer · NCT01189487 · 47 enrolled · Japan
- Dec 19, 2012Xiangbei Welman Pharmaceutical's first study: phase 4 study in Respiratory Tract InfectionsNew to Xiangbei Welman PharmaceuticalXiangbei Welman Pharmaceutical · NCT01760109 · 2,000 enrolled · China
- Aug 22, 2019Phase 4 study in Respiratory Tract InfectionsXiangbei Welman Pharmaceutical · NCT04066621 · 30 enrolled
- Dec 11, 2019Phase 4 study in GonorrheaXiangbei Welman Pharmaceutical · NCT04202068 · 113 enrolled
- Dec 8, 2022Yung Shin Pharm. Ind.'s first study: phase 4 study in Communicable DiseasesNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT05654090 · 14 enrolled · Taiwan
- Jan 16, 2025Innoviva Specialty Therapeutics's first study: phase 1 study in Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)New to Innoviva Specialty TherapeuticsInnoviva Specialty Therapeutics · NCT06801223 · 48 planned · United States
Ahead
- May 5, 2028Primary completion: phase 1 study in Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)Innoviva Specialty Therapeutics · NCT06801223
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial beta-lactamase TEM inhibitor”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06801223Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) · United States | 1 | Recruiting | Innoviva Specialty Therapeutics | May 5, 2028 | 48 |
| NCT05654090Communicable Diseases · Taiwan | 4 | UNKNOWN | Yung Shin Pharm. Ind. | Nov 18, 2022 | 14 |
| NCT04202068Gonorrhea | 4 | Completed | Xiangbei Welman Pharmaceutical | May 3, 2016 | 113 |
| NCT04066621Respiratory Tract Infections | 4 | Completed | Xiangbei Welman Pharmaceutical | Jun 11, 2016 | 30 |
| NCT01760109Respiratory Tract Infections · China | 4 | Completed | Xiangbei Welman Pharmaceutical | Jun 2016 | 2,000 |
| NCT01189487Pneumonia, Bacterial · Japan | 3 | Completed | Pfizer | Apr 2011 | 47 |
| NCT00137007Pneumonia | 4 | Completed | Pfizer | 151 |
How it is read
Names in the registry
- “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)”, 1 entry
- “Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)”, 1 entry
- “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)”, 1 entry
- “Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)”, 1 entry
- “cefoperazone sodium and sulbactam sodium”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Tract Infections, 2 studies
- Communicable Diseases, 1 study
- Gonorrhea, 1 study
- Pneumonia, Bacterial, 1 study
- Pneumonia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.